Pharmacoeconomic evaluation of the accelerated recovery and blood saving program in extended combined operations on the pelvic organs

Background: The newly diagnosed pelvic cancer appears to be locally advanced in every third patient, which requires a comprehensive approach to treatment and often extensive combined surgical interventions. Long duration of operations, blood loss, complications of the tumor process during or after previous treatment often lead to the development of complications, slow rehabilitation and increasing cost of treatment. The use of fast track protocol (FTP) and blood-saving technologies can reduce the impact of these adverse factors.Aim: The evaluation of the pharmaco-economic efficiency of fast track protocol and blood-saving technologies in patients after extended combined operations for pelvic tumors.Materials and methods: The study included 111 patients with pelvic tumors who underwent an extensive combined surgery for rectal or gynecological tumors. Among them, 52 patients were underwent the same fast track protocol with a focus on the use of blood-saving technologies (2020-2021), the management of patients in the control group was more conservative (n = 59, 2018-2019). After analyzing the factors affecting the treatment outcomes, 2 groups of 16 patients comparable in basic clinical indications were formed by selection of pairs patients using quasi-randomization to assess the direct costs of treatment.Results: The cost of treatment in the FTS group and the control group was 157744 ± 32728,72 and 273429 ± 217931,5 (P function show_eabstract() { $('#eabstract1').hide(); $('#eabstract2').show(); $('#eabstract_expand').hide(); }